Trial Profile
Study of the pharmacokinetic and pharmacodynamic and safety properties of Tinapeg (6 mg/0.6 ml syringes, AryaTinaGene Biopharmaceutical Co) in comparison to Neulastim (6 mg/0.6 ml syringes, Amgen) in healthy volunteers
Status:
Active, no longer recruiting
Phase of Trial:
Phase IV
Latest Information Update: 13 Nov 2018
Price :
$35
*
At a glance
- Drugs Pegfilgrastim (Primary)
- Indications Febrile neutropenia
- Focus Pharmacodynamics; Pharmacokinetics
- Sponsors AryaTinaGene Biopharmaceuticals
- 13 Nov 2018 New trial record